Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development ...Middle East

PR Newswire - News
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
CARLSBAD, Calif., Nov. 23, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis...

Hence then, the article about ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis nash enters development was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News